Chris Bowden, MD

Dr. Bowden is the CMO of Remix, a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease. He previously served as Strategic Advisor and Chief Medical Officer (CMO) at Agios, overseeing the company’s clinical development that led to US approvals for the IDH inhibitors IDHIFA and TIBSOVO in AML, for TIBSOVO in cholangiocarcinoma and for PYRUKYND, a Pyruvate Kinase activator, for adults with Pyruvate Kinase Deficiency. Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech, Inc. where he was responsible for the successful development of several novel targeted oncology medicines, including Zelboraf™ and Tarceva™. Before that, Dr. Bowden was the executive director for EMEA regions for Bristol-Myers Squibb where he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development at Pharmacia Corporation and Janssen Pharmaceutical, Inc. Prior to his industry work, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center.

Dr. Bowden received his M.D. from Hahnemann University School of Medicine in Philadelphia after which he completed his internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He conducted his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology.